An expert from the CURE® advisory board explains the likely treatability of Dave Coulier’s non-Hodgkin lymphoma.

A haematologist shares insights into the challenges of the disease and the promise of emerging treatment options.

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in ...

Julio Chavez, MD, MS, discusses some of the important studies and research being presented at the 2024 American Society of ...

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...

In the real world, treating relapsed/refractory large B-cell lymphoma with epcoritamab and glofitamab leads to poorer ...

Roche has shared new long-term results from a phase 3 study of its anti-CD79b antibody-drug conjugate Polivy (polatuzumab ...

A study in mice offers evidence that inhibiting EZH2 can enhance lymphoma immunogenicity and overcome CAR-T cell therapy resistance.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the ...

AbbVie (ABBV) announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody ...

Genmab (GMAB) announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody ...